Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Country
- 🇨🇳China
- Ownership
- Joint Venture, Subsidiary
- Established
- 1997-04-16
- Employees
- -
- Market Cap
- -
- Website
- http://www.cttq.com
Efficacy and Safety of Angiotensin II Injection Versus Placebo in Patients With Refractory Distributed Shock
- Conditions
- Interventions
- First Posted Date
- 2024-04-08
- Last Posted Date
- 2024-04-08
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 214
- Registration Number
- NCT06351150
- Locations
- 🇨🇳
The First Affiliated Hospital of Sun Yat sen University, Guangzhou, Guangdong, China
🇨🇳Zhujiang Hospital of Southern Medical University, Guangzhou, Guangdong, China
🇨🇳The First Affiliated Hospital of Shantou University Medical College, Shantou, Guangdong, China
A Clinical Trial of TQB3006 Tablets in Patients With Advanced Malignant Cancer
- First Posted Date
- 2024-04-03
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 112
- Registration Number
- NCT06344351
- Locations
- 🇨🇳
Chongqing university Cancer Hospital, Chongqing, Chongqing, China
🇨🇳Peking University Shougang Hospital, Beijing, Beijing, China
🇨🇳Anhui Provincial Hospital, Hefei, Anhui, China
A Trial to Assess the Bioequivalence of Generic Tiotropium Bromide Inhalation Powder and Reference Product in Healthy Adult Participants Under Fasting Conditions (Pilot)
- Conditions
- Interventions
- First Posted Date
- 2024-03-22
- Last Posted Date
- 2024-03-29
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 39
- Registration Number
- NCT06326671
- Locations
- 🇨🇳
Henan (Zhengzhou) Zhonghui Cardiovascular Hospital, Zhengzhou, Henan, China
Clinical Study of TQB2223 Injection Combined With AK105 Injection in the Treatment of Advanced Hepatocellular Carcinoma.
- Conditions
- Interventions
- First Posted Date
- 2024-03-20
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06320080
- Locations
- 🇨🇳
Affiliated Cancer Hospital of Harbin Medical University, Harbin, Heilongjiang, China
🇨🇳Hubei Provincial Tumor Hospital, Wuhan, Hubei, China
🇨🇳Hunan Provincial Tumor Hospital, Changsha, Hunan, China
A Clinical Trial of TQ05105 Tablets in the Treatment of Chronic Graft-versus-host Disease
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-06-20
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 40
- Registration Number
- NCT06300320
- Locations
- 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳Guangzhou First People's Hospital, Guangzhou, Guangdong, China
🇨🇳The Affiliated People's Hospital of Ningbo University, Ningbo, Zhejiang, China
D-1553 Tablet Versus Docetaxel Injection for KRAS G12C Mutation-positive Locally Advanced or Metastatic Non-small Cell Lung Cancer After Prior Standard Therapy Failure
- Conditions
- Interventions
- First Posted Date
- 2024-03-08
- Last Posted Date
- 2024-04-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 522
- Registration Number
- NCT06300177
- Locations
- 🇨🇳
Weihai Municipal Hospital, Weihai, Shandong, China
🇨🇳Shanghai Chest Hospital, Shanghai, Shanghai, China
🇨🇳Anhui Province Hospital, Hefei, Anhui, China
TQB2928 Injection Combined With Penpulimab in Treatment of Advanced Malignant Tumors.
- Conditions
- Interventions
- First Posted Date
- 2024-03-07
- Last Posted Date
- 2024-08-06
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 3
- Registration Number
- NCT06297642
- Locations
- 🇨🇳
Cancer Hospital Chinese Academy of Medical Science, Beijing, Beijing, China
🇨🇳The Second People's Hospital of Hefei, Hefei, Anhui, China
🇨🇳Lu'an People's Hospital of Anhui Province, Lu'an, Anhui, China
A Clinical Study of AL2846 Capsule Combined With Gemzar Injection in the Treatment of Advanced Pancreatic Cancer
- First Posted Date
- 2024-02-26
- Last Posted Date
- 2024-02-26
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 34
- Registration Number
- NCT06278493
- Locations
- 🇨🇳
Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China
A Clinical Trial of TQ05105 Tablets Combined With TQB3909 Tablets in the Treatment of Myelofibrosis (MF)
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-07-25
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 93
- Registration Number
- NCT06245941
- Locations
- 🇨🇳
Hennan Cancer Hospital, Zhengzhou, Henan, China
🇨🇳Xijing Hospital of the Fourth Military Medical University, Xian, Shaanxi, China
🇨🇳The Second People's Hospital of Hefei, Hefei, Anhui, China
A Study of TQB3454 Tablets in Patients With Blood Tumors
- Conditions
- Interventions
- First Posted Date
- 2024-01-23
- Last Posted Date
- 2024-01-23
- Lead Sponsor
- Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- Target Recruit Count
- 80
- Registration Number
- NCT06218771
- Locations
- 🇨🇳
Xinhua Hospital affiliated to Shanghai Jiaotong University School of Medicine, Shanghai, Shanghai, China
🇨🇳Hospital of Hematology, Chinese Academy of Medical Sciences, Tianjin, Tianjin, China
🇨🇳The Affiliated Hospital of Chengde Medical College, Chengde, Hebei, China